Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sinovac Q2 Revenues Climb 73%

publication date: Aug 13, 2008

Sinovac Biotech Ltd. reported that its revenues in Q2 rose 73% to $16.5 million. The increase was partly due to a $4.6 million government order for the company’s vaccines following the May 2008 Sichuan earthquake. Without the government order, Sinovac’s revenues would have been higher by only 25%. Sinovac’s main revenue driver is Healive®, a vaccine for hepatitis A. The company’s Q2 net income of $3.3 million almost equaled its 2007 first half (six months) profit of $3.5 million. More details...

Stock Symbol: (AMEX: SVA)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here